

Pathogenreduktion von Blutprodukten – ein Paradigmenwechsel in der Transfusionsmedizin

- 1) Engelfriet CP, Reesink HW, Snyder EL, Dzik WH, Masse M, Naegelen C, Brand A, Williamson L, Knipe J, Bruce M, Woodfield DG, Sekiguchi S, Myllyla G, Sablinski J, Zupanska B:
The official requirements for platelet concentrates.
Vox Sang 1998;**75**:308-317.
- 2) Devine DV, Bradley AJ, Maurer E, Levin E, Chahal S, Serrano K, Gyongyossy-Issa MI:
Effects of prestorage white cell reduction on platelet aggregate formation and the activation state of platelets and plasma enzyme systems.
Transfusion 1999;**39**:724-734.
- 3) Harrington T, Kuehnert MJ, Kamel H, Lanciotti RS, Hand S, Currier M, Chamberland ME, Petersen LR, Marfin AA:
West Nile virus infection transmitted by blood transfusion.
Transfusion 2003;**43**:1018-1022.
- 4) Bianco C:
Dengue and Chikungunya viruses in blood donations: risks to the blood supply?
Transfusion 2008;**48**:1279-128.
- 5) Klein HG, Anderson D, Bernardi MJ, Cable R, Carey W, Hoch JS, Robitaille N, Sivilotti ML, Smaill F:
Pathogen inactivation: making decisions about new technologies. Report of a consensus conference.
Transfusion 2007;**47**:2338-2347.
- 6) Pereira A:
Methylene-blue-photoinactivated plasma and its contribution to blood safety.
Transfusion 2004;**44**:948-950; author reply 950.
- 7) Pelletier JP, Transue S, Snyder EL:
Pathogen inactivation techniques.
Best Pract Res Clin Haematol 2006;**19**:205-242.
- 8) Irsch J, Lin L:
Pathogen Inactivation of Platelet and Plasma Blood Components for Transfusion Using the INTERCEPT Blood System™.
Transfusion Medicine and Hemotherapy 2011;**38**:19-31.
- 9) Marschner S, Goodrich R:
Pathogen Reduction Technology Treatment of Platelets, Plasma and Whole Blood Using Riboflavin and UV Light.
Transfusion Medicine and Hemotherapy 2011;**38**:8-18.
- 10) Seltsam A, Mueller TH:
UVC irradiation for pathogen reduction of platelet concentrates and plasma.
Transfus Med Hemother 2011;**38**:43-54.
- 11) Henschler R, Seifried E, Mufti N:
Development of the S-303 Pathogen Inactivation Technology for Red Blood Cell Concentrates.
Transfusion Medicine and Hemotherapy 2011;**38**:33-42.
- 12) Schlenke P, Hervig T, Isola H, Wiesel ML, Kientz D, Pinkoski L, Singh Y, Lin L, Corash L, Cazenave JP:
Photochemical treatment of plasma with amotosalen and UVA light: process validation in three European blood centers.
Transfusion 2008;**48**:697-705.
- 13) Ettinger A, Miklausz MM, Hendrix BK, Bihm DJ, Maldonado-Codina G, Goodrich RP:
Protein stability of previously frozen plasma, riboflavin and UV light-treated, refrozen and stored for up to 2 years at -30 degrees C.
Transfus Apher Sci 2011;**44**:25-31.

- 14) Mintz PD, Bass NM, Petz LD, Steadman R, Streiff M, McCullough J, Burks S, Wages D, Van Doren S, Corash L:
Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease.
Blood 2006.
- 15) Mintz PD, Neff A, MacKenzie M, Goodnough LT, Hillyer C, Kessler C, McCrae K, Menitove JE, Skikne BS, Damon L, Lopez-Plaza I, Rouault C, Crookston KP, Benjamin RJ, George J, Lin JS, Corash L, Conlan MG:
A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura.
Transfusion 2006;**46**:1693-1704.
- 16) Cazenave JP, Waller C, Kientz D, Mendel I, Lin L, Jacquet M, Propst M, Liu W, Corash L, Sundin D, Defoin L, Messe N, Osselaer JC:
An active hemovigilance program characterizing the safety profile of 7483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment.
Transfusion 2010;**50**:1210-1219.
- 17) McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A, Snyder E, Stadtmayer EA, Lopez-Plaza I, Coutre S, Strauss RG, Goodnough LT, Frisley JL, Raife T, Cable R, Murphy S, Howard Ft, Davis K, Lin JS, Metzel P, Corash L, Koutsoukos A, Lin L, Buchholz DH, Conlan MG:
Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial.
Blood 2004;**104**:1534-1541.
- 18) van Rhenen D, Gulliksson H, Cazenave JP, Pamphilon D, Ljungman P, Kluter H, Vermeij H, Kappers-Klunne M, de Greef G, Laforet M, Lioure B, Davis K, Marblie S, Mayaudon V, Flament J, Conlan M, Lin L, Metzel P, Buchholz D, Corash L:
Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euro-SPRITE trial.
Blood 2003;**101**:2426-2433.
- 19) Kerkhoffs JL, van Putten WL, Novotny VM, Te Boekhorst PA, Schipperus MR, Zwaginga JJ, van Pampus LC, de Greef GE, Luten M, Huijgens PC, Brand A, van Rhenen DJ:
Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction.
Br J Haematol 2010;**150**:209-217.
- 20) *A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology.* *Transfusion* 2010;**50**:2362-2375.
- 21) Cazenave JP, Isola H, Waller C, Mendel I, Kientz D, Laforet M, Raidot JP, Kandel G, Wiesel ML, Corash L:
Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period.
Transfusion 2011;**51**:622-629.
- 22) Gelderman MP, Chi X, Zhi L, Vostal JG:
Ultraviolet B light-exposed human platelets mediate acute lung injury in a two-event mouse model of transfusion.
Transfusion 2011.
- 23) Corash L, Lin JS, Sherman CD, Eiden J:
Determination of acute lung injury after repeated platelet transfusions.
Blood 2011;**117**:1014-1020.
- 24) Benjamin RJ, McCullough J, Mintz PD, Snyder E, Spotnitz WD, Rizzo RJ, Wages D, Lin JS, Wood L, Corash L, Conlan MG:
Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patients.
Transfusion 2005;**45**:1739-1749.
- 25) North AK, Henschler R, Geisen C, Garratty G, Arndt PA, Kattamis A, Cohen A, Piga A, Arslan O, Galanello R:
Evaluation of naturally occurring antibodies to pathogen inactivated red blood cells.
Transfusion 2010;**50** (suppl):38A.

-
- 26) Festlegung der Haltbarkeitsfrist von Thrombozytenkonzentraten mit dem Ziel der Reduktion lebensbedrohlicher septischer Transfusionsreaktionen durch bakterielle Kontamination.
Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 2008;**51**:1484.
- 27) Rasongles P, Angelini-Tibert MF, Simon P, Currie C, Isola H, Kientz D, Slaedts M, Jacquet M, Sundin D, Lin L, Corash L, Cazenave JP: Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a Chikungunya virus epidemic in Ile de La Reunion.
Transfusion 2009;**49**:1083-1091.
- 28) Goodrich RP, Gilmour D, Hovenga N, Keil SD:
A laboratory comparison of pathogen reduction technology treatment and culture of platelet products for addressing bacterial contamination concerns.
Transfusion 2009.
- 29) Mohr H, Steil L, Gravemann U, Thiele T, Hammer E, Greinacher A, Muller TH, Volker U:
A novel approach to pathogen reduction in platelet concentrates using short-wave ultraviolet light.
Transfusion 2009;**49**:2612-2624.
- 30) Kleinman S, Cameron C, Custer B, Busch M, Katz L, Kralj B, Matheson I, Murphy K, Preiksaitis J, Devine D:
Modeling the risk of an emerging pathogen entering the Canadian blood supply.
Transfusion 2010;**50**:2592-2606.
- 31) Postma MJ, van Hulst M, De Wolf JT, Botteman M, Staginnus U:
Cost-effectiveness of pathogen inactivation for platelet transfusions in the Netherlands.
Transfus Med 2005;**15**:379-387.
- 32) Janssen MP, van der Poel CL, Buskens E, Bonneux L, Bonsel GJ, van Hout BA:
Costs and benefits of bacterial culturing and pathogen reduction in the Netherlands.
Transfusion 2006;**46**:956-965.